shire
- 23andMe
- Abbott
- Abbvie
- AC Immune
- Acorda Therapeutics
- AdnaGen
- Agilent Technologies
- Alere
- Alexion Pharmaceuticals
- Amgen
- Astellas
- AstraZeneca
- Audentes Therapeutics
- Beckman Coulter
- Berkeley Lights
- Bio-Rad Laboratories
- Biogen
- BioServe Biotechnologies
- Cancer Genetics
- Catalent
- Chan Soon-Shiong Institute for Molecular Medicine
- Charles RIver Laboratories
- Color Genomics
- Cynvenio Biosystem
- Dana-Farber Cancer Institute
- deCODE genetics
- Dicerna
- Dimension Therapeutics
- Exact Sciences
- Foundation Medicine
- GE Healthcare
- GeneInsight
- Gilead Sciences
- GlaxoSmithKline
- Halozyme Therapeutics
- Hitachi High-Technologies
- Horizon Discovery Group
- Human Longevity
- Illumina
- Invitae
- Jackson Laboratory
- Janssen Biotech
- LabCorp
- Maravai LifeSciences
- MD Anderson
- MDxHealth
- MedImmune
- Memorial Sloan Kettering Cancer Center
- Merck & Co
- Merck KGaA
- NanoString Technologies
- Novartis
- Pathology
- PerkinElmer
- PersonalizeDx
- Qiagen
- R-Biopharm
- RayBiotech
- Roche
- Sanofi
- shire
- Sigma-Aldrich
- Stand Up to Cancer
- Synthego
- Takeda
- Thermo Fisher Scientific
- TriLink Biotechnologies
- Trovagene
- UCB Biosciences
![Sanofi’s global vaccines unit Sanofi Pasteur has launched an up-to-$805 million partnership with Translate Bio to develop messenger RNA vaccines for up to five undisclosed infectious disease pathogens. [Ryan Jeffs/Wikicommons]](https://www.genengnews.com/wp-content/uploads/2018/08/Mar14_2017_WikiCommons_MicroRNAAndmRNAVisualization2173942127-265x198.jpg "Sanofi Pasteur, Translate Bio Launch mRNA Vaccine Partnership")
